10x Genomics (TXG) 10-K 18 Feb 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Jan. 31, 2022	Jun. 30, 2021
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	(925)
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 18.7
Documents Incorporated by Reference	Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2022 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2021.
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		93,298,507
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		19,546,465

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	San Jose, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 587,447	$ 663,603
Restricted cash	1,028	16,567
Accounts receivable, net	85,254	51,208
Inventory	59,966	29,959
Prepaid expenses and other current assets	13,896	13,029
Total current assets	747,591	774,366
Property and equipment, net	169,492	72,840
Restricted cash	7,598	8,474
Operating lease right-of-use assets	60,918	46,983
Goodwill	4,511	0
Intangible assets, net	25,397	22,354
Other noncurrent assets	3,319	4,324
Total assets	1,018,826	929,341
Current liabilities:
Accounts payable	17,351	4,709
Accrued compensation and related benefits	31,626	15,383
Accrued expenses and other current liabilities	50,909	43,453
Deferred revenue	5,340	4,472
Accrued contingent liabilities	5,131	5,936
Accrued contingent liabilities	0	44,173
Total current liabilities	110,357	118,126
Accrued license fee, noncurrent	5,814	11,171
Operating lease liabilities, noncurrent	76,847	57,042
Other noncurrent liabilities	8,240	3,930
Total liabilities	201,258	190,269
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2021 and December 31, 2020	0	0
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 112,514,977 (Class A 92,868,512, Class B 19,646,465) and 108,485,909 (Class A 85,804,444, Class B 22,681,465) shares issued and outstanding as of December 31, 2021 and 2020	2	2
Additional paid-in capital	1,680,865	1,544,218
Accumulated deficit	(863,321)	(805,098)
Accumulated other comprehensive gain (loss)	22	(50)
Total stockholders’ equity	817,568	739,072
Total liabilities and stockholders’ equity	$ 1,018,826	$ 929,341

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred Stock, Par Value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized (in shares)	1,100,000,000	1,100,000,000
Common Stock, Shares, Issued (in shares)	112,514,977	108,485,909
Common Stock, Shares, Outstanding (in shares)	112,514,977	108,485,909
Common Class A
Common Stock, Par Value (in dollars per share)	$ 0.00001
Common Stock, Shares Authorized (in shares)	1,000,000,000
Common Stock, Shares, Issued (in shares)	92,868,512	85,804,444
Common Stock, Shares, Outstanding (in shares)	92,868,512	85,804,444
Common class B
Common Stock, Par Value (in dollars per share)	$ 0.00001
Common Stock, Shares Authorized (in shares)	100,000,000
Common Stock, Shares, Issued (in shares)	19,646,465	22,681,465
Common Stock, Shares, Outstanding (in shares)	19,646,465	22,681,465

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 490,490	$ 298,845	$ 245,893
Cost of revenue	74,091	58,468	61,033
Gross profit	416,399	240,377	184,860
Operating expenses:
Research and development	211,752	123,375	83,097
In-process research and development	0	447,548	0
Selling, general and administrative	257,560	202,326	130,834
Accrued contingent liabilities	(660)	1,270	1,502
Total operating expenses	468,652	774,519	215,433
Loss from operations	(52,253)	(534,142)	(30,573)
Other income (expense):
Interest income	206	1,532	2,805
Interest expense	(866)	(1,682)	(3,079)
Other (expense) income, net	(802)	1,337	(186)
Loss on extinguishment of debt	0	(1,521)	0
Total other expense	(1,462)	(334)	(460)
Loss before provision for income taxes	(53,715)	(534,476)	(31,033)
Provision for income taxes	4,508	8,255	218
Net loss	(58,223)	(542,731)	(31,251)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	72	(4)	(9)
Comprehensive loss	$ (58,151)	$ (542,735)	$ (31,260)
Net loss per share, basic (in dollars per share)	$ (0.53)	$ (5.37)	$ (0.80)
Net loss per share, diluted (in dollars per share)	$ (0.53)	$ (5.37)	$ (0.80)
Weighted-average shares used to compute net loss per share, basic (in shares)	110,347,937	101,151,675	39,091,366
Weighted-average shares used to compute net loss per share, diluted (in shares)	110,347,937	101,151,675	39,091,366

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Convertible Preferred Stock	Common Class A	Common Class ACommon Stock	Common Class AAdditional Paid-in Capital	Series D1 convertible preferred stock	Common Class B	Common Class BCommon Stock	Common Class BAdditional Paid-in Capital
Beginning balance of temporary equity (in shares) at Dec. 31, 2018						67,704,278
Beginning balance of temporary equity at Dec. 31, 2018						$ 243,244
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of convertible preferred stock into Class B common stock (in shares)										(67,704,278)
Conversion of convertible preferred stock into Class B common stock										$ (243,244)
Ending balance of temporary equity (in shares) at Dec. 31, 2019						0
Ending balance of temporary equity at Dec. 31, 2019						$ 0
Beginning balance (in shares) at Dec. 31, 2018		14,549,801
Beginning balance at Dec. 31, 2018	$ (219,987)	$ 1	$ 11,165	$ (231,116)	$ (37)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock upon exercise of options (in shares)								2,226,493
Issuance of Class A common stock upon exercise of options							$ 3,435		$ 3,435
Conversion of convertible preferred stock into Class B common stock (in shares)												67,704,278
Conversion of convertible preferred stock into Class B common stock											$ 243,244	$ 1	$ 243,243
Issuance of Class A common stock upon initial public offering, net of issuance costs (in shares)								11,500,000
Issuance of Class A common stock upon initial public offering, net of issuance costs							410,824		410,824
Cashless exercise of Class A common stock warrants (in shares)								261,024
Vesting of shares subject to repurchase, including early exercised options	494		494
Stock-based compensation	13,333		13,333
Net loss	(31,251)			(31,251)
Other comprehensive income	(9)				(9)
Ending balance (in shares) at Dec. 31, 2019		96,241,596
Ending balance at Dec. 31, 2019	420,083	$ 2	682,494	(262,367)	(46)
Ending balance of temporary equity (in shares) at Dec. 31, 2020						0
Ending balance of temporary equity at Dec. 31, 2020						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock upon initial public offering, net of issuance costs (in shares)								4,600,000
Issuance of Class A common stock upon initial public offering, net of issuance costs							482,267		482,267
Issuance of Class A common stock related to equity awards (in shares)								5,742,931
Issuance of Class A common stock related to equity awards							23,743		23,743
Issuance of Class A common stock for asset acquisition (in shares)								1,901,382
Issuance of Class A common stock for asset acquisition							306,000		306,000
Vesting of shares subject to repurchase, including early exercised options	247		247
Stock-based compensation	49,467		49,467
Net loss	(542,731)			(542,731)
Other comprehensive income	(4)				(4)
Ending balance (in shares) at Dec. 31, 2020		108,485,909
Ending balance at Dec. 31, 2020	739,072	$ 2	1,544,218	(805,098)	(50)
Ending balance of temporary equity (in shares) at Dec. 31, 2021						0
Ending balance of temporary equity at Dec. 31, 2021						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)								4,029,068
Issuance of Class A common stock related to equity awards							$ 40,325		$ 40,325
Vesting of shares subject to repurchase, including early exercised options	154		154
Stock-based compensation	96,168		96,168
Net loss	(58,223)			(58,223)
Other comprehensive income	72				72
Ending balance (in shares) at Dec. 31, 2021		112,514,977
Ending balance at Dec. 31, 2021	$ 817,568	$ 2	$ 1,680,865	$ (863,321)	$ 22

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net loss	$ (58,223)	$ (542,731)	$ (31,251)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	21,118	14,012	7,066
Stock-based compensation expense	95,962	48,626	13,333
Loss on disposal of property and equipment	79	29	614
Loss on extinguishment of debt	0	1,521	0
Amortization of right-of-use assets	7,136	5,009	0
Class A common stock issued for in-process research and development	0	306,000	0
Accretion of discount on term loan	0	17	101
Changes in operating assets and liabilities:
Accounts receivable	(34,041)	(17,847)	(5,284)
Inventory	(30,132)	(14,601)	(6,699)
Prepaid expenses and other current assets	(1,053)	(5,265)	(3,535)
Other noncurrent assets	1,045	(2,686)	(251)
Accounts payable	11,084	(7,770)	4,901
Accrued compensation and other related benefits	16,337	2,936	5,292
Deferred revenue	1,535	2,023	634
Accrued contingent liabilities	(44,173)	(24,485)	30,658
Accrued expenses and other current liabilities	(873)	25,917	5,771
Deferred rent, noncurrent	0	0	12,730
Operating lease liability	(2,469)	(4,832)	0
Other noncurrent liabilities	(4,705)	(3,771)	547
Net cash (used in) provided by operating activities	(21,373)	(217,898)	34,627
Investing activities:
Purchases of property and equipment	(101,278)	(36,666)	(42,742)
Acquisition of business, net of cash acquired	(5,451)	0	0
Acquisition of intangible assets	0	(1,728)	(25)
Net cash used in investing activities	(106,729)	(38,394)	(42,767)
Financing activities:
Payments on term loans	0	(31,256)	0
Proceeds from borrowings under revolver	0	0	11,000
Payments on borrowings under revolver	0	0	(11,000)
Payments on technology license financing arrangement	(5,028)	(5,848)	0
Proceeds from issuance of common stock upon initial and follow-on public offerings, net of issuance costs	0	482,267	410,824
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	40,325	23,743	3,766
Net cash provided by financing activities	35,297	468,906	414,590
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	234	(463)	(45)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(92,571)	212,151	406,405
Cash, cash equivalents, and restricted cash at beginning of year	688,644	476,493	70,088
Cash, cash equivalents, and restricted cash at end of year	596,073	688,644	476,493
Supplemental disclosures of cash flow information:
Cash paid for interest	1,222	1,670	2,250
Cash paid for taxes	8,660	280	22
Noncash investing and financing activities
Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities	16,972	2,983	4,492
Right-of-use assets obtained in exchange for new operating lease liabilities	21,284	13,562	0
Contingent consideration payable related to business acquisition	1,500	0	0
Conversion of convertible preferred stock into common stock upon initial public offering	0	0	243,244
Purchase of technology licenses under financing arrangement	$ 0	$ 0	$ 22,099

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012 and is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium Controller, Chromium Connect and Chromium X Series instruments, which the Company refers to as “instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for our Visium solution, which does not require a 10x Genomics instrument, and our Chromium solution, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe and North America. Basis of Presentation

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, accounting for asset and business acquisitions and the valuation of stock-based compensation awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation may be affected. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value. Short-term restricted cash of $1.0 million and long-term restricted cash of $7.6 million primarily represents cash on deposit with financial institutions as security for letters of credit outstanding for the benefit of the landlord related to the Company’s non-cancelable operating leases for its corporate headquarters (see “—Commitments and Contingencies” below). The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2021 2020 2019 Cash and cash equivalents $ 587,447 $ 663,603 $ 424,166 Restricted cash 8,626 25,041 52,327 Total cash, cash equivalents and restricted cash $ 596,073 $ 688,644 $ 476,493 Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Money market funds are highly liquid investments which are actively traded. The pricing information for the Company’s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. As of December 31, 2021 and December 31, 2020, the Company held $548.0 million and $600.9 million in money market funds, respectively, with no unrealized gains or losses. Accounts Receivable, Net Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. There was no allowance for doubtful accounts as of December 31, 2021 and December 31, 2020. Business Concentrations The Company’s instruments are mostly assembled and tested by a single contract manufacturer in Asia and the United States. The Company’s agreement with the contract manufacturers contains purchase commitments. In addition, the Company is reliant on several suppliers for key components for its reagent kits. A significant disruption in the operations of the contract manufacturers or suppliers may impact the production of the Company’s products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations, which may be partially mitigated by the contract manufacturer's ability to relocate operations from Asia location to United States. Concentrations Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents held with large financial institutions in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of these financial institutions. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced material credit losses to date. For the years ended December 31, 2021, 2020, and 2019, no single customer represented more than 10% of revenue. As of December 31, 2021, one of the Company's distributors accounted for 11% of the Company’s outstanding accounts receivable. No other customer or distributor represented more than 10% of the Company’s outstanding accounts receivable as of December 31, 2021 and December 31, 2020. Substantially all the Company’s long-lived assets are located in the United States. Inventory Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s consolidated statements of operations. Leases The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company gives consideration to its credit risk, term of the lease and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and costs of goods sold over the reasonably assured lease term. The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less. Internal-Use Software The Company capitalizes costs incurred to develop internal-use software within fixed assets and commencing from 2020, began capitalizing costs to develop hosting arrangements within other noncurrent assets in the consolidated balance sheets. Costs incurred during the preliminary planning and evaluation and post implementation stages of the project are expensed as incurred. Costs incurred during the application development stage of the project are capitalized. These costs are amortized on a straight-line basis over the estimated useful life of the asset. Property and Equipment, Net Property and equipment is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the following assets: Useful Life (Years) Laboratory equipment and machinery 3 - 5 Computer equipment 2 - 3 Furniture and fixtures 3 Leasehold improvements 1 - 10 Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no impairment losses recorded for the years ended December 31, 2021, 2020 and 2019. Product Warranties The Company generally provides a one-year warranty on its instruments. The Company reviews its exposure to estimated warranty obligations associated with instrument sales and establishes an accrual based on historical product failure rates and actual warranty costs incurred. This expense is recorded as a component of cost of revenue in the consolidated statements of operations and comprehensive loss. Deferred Revenue Deferred revenue consists of payments received in advance of revenue recognition primarily related to instrument service agreements, also referred to as extended warranties. Revenue under these agreements is recognized over the related service period. Deferred revenue expected to be recognized during the 12 months following the balance sheet date is recorded as current portion of deferred revenue and the remaining portion is recorded as long-term. Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Cost of Revenue Cost of revenue primarily consists of manufacturing costs incurred in the production process, including personnel and related costs, component materials, labor and overhead, packaging and delivery costs and allocated costs including facilities and information technology. In addition, cost of product revenue includes royalty costs for licensed technologies included in the Company’s products, warranty costs and provisions for slow-moving and obsolete inventory. Shipping and Handling Costs Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are included in the Company’s cost of revenue. Research and Development Research and development costs are expensed in the period incurred. Research and development expense consists of personnel and related costs, independent contractor costs, laboratory supplies, equipment maintenance, prototype and materials expenses, amortization of developed technology and intangibles and allocated costs including facilities and information technology. See Note 3 for discussion of in-process research and development included on the consolidated statements of operations. Advertising Costs Advertising costs are expensed as incurred. The Company incurred advertising costs of $4.7 million, $1.9 million, and $1.5 million for the years ended December 31, 2021, 2020, and 2019, respectively. Stock-Based Compensation The Company’s stock-based compensation relates to stock options, restricted stock units (“RSUs”) and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). Stock-based compensation expense for its stock-based awards is based on their grant date fair value. The Company determines the fair value of RSUs based on the closing price of its stock, which is listed on Nasdaq, at the date of the grant. The Company estimates the fair value of stock option awards and stock purchase rights under an ESPP on the grant date using the Black-Scholes option-pricing model. The fair values of stock-based awards are recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company calculated the expected term using the simplified method, which is the mid-point between the vesting and contractual term. Due to the short trading period of the Company's stock, the Company has estimated volatility by reference to the historical volatilities of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award. Foreign Currency For foreign subsidiaries where the functional currency is the local currency, assets and liabilities are translated to the U.S. dollar using month-end exchange rates, and revenue and expenses using average exchange rates. The adjustments resulting from these foreign currency translations are recorded in Accumulated other comprehensive gain (loss). For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company recognized foreign currency transaction losses of $0.9 million for the year ended December 31, 2021, and foreign currency transaction gains of $1.3 million and $0.1 million for the years ended December 31, 2020 and 2019, respectively. Income Taxes The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply in the years in which those tax assets and liabilities are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. federal state and foreign tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. The Company’s participating securities included the Company’s convertible preferred stock, as the holders would have been entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend was paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business in which case the transaction is accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date, and that the fair value of acquired intangibles be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the purchase price over the assigned fair values of the net assets acquired is recorded as goodwill. Goodwill is not amortized, rather assessed, at least annually, for impairment at a reporting unit level. During the goodwill impairment review, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting unit with the carrying value, including goodwill. If the carrying amounts of the reporting unit exceed the fair value, we record an impairment loss based on the difference. The Company accounts for an asset acquisition under ASC, Business Combinations Topic 805, Subtopic 50 , which requires the acquiring entity in an asset acquisition to recognize net assets based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition; any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on relative fair values. In-process research and development expense is expensed as incurred provided there is no alternative future use. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions 2021 Acquisition Tetramer Shop Acquisition On January 8, 2021 (the "acquisition date"), the Company purchased 100% of the outstanding shares of Tetramer Shop ApS (“Tetramer Shop”), a privately held company based in Copenhagen, Denmark, for a total cash consideration of $8.5 million, net of cash acquired of $0.2 million and including $1.5 million of fair value of contingent consideration. The contingent consideration is recorded as a liability and is payable upon the successful transfer of Tetramer Shop's technology to the Company within two years of the acquisition date. Tetramer Shop is a life sciences technology company which develops and provides reagents for precise monitoring of antigen-specific T-cells in research and development. The Company acquired Tetramer Shop for its expertise in building empty, loadable major histocompatibility complex (MHC) molecules. The acquisition was accounted for using the acquisition method of accounting, with Tetramer Shop treated as the acquiree. The acquired assets, including identified intangible assets, and liabilities were recorded at their respective fair values with an amount recorded to goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. The fair values assigned to the assets acquired and liabilities assumed were based on management’s assumptions as of the reporting date. Our consolidated statements of income include the financial results of Tetramer Shop subsequent to the acquisition date. Revenue related to Tetramer Shop since the acquisition date was included in our consolidated statements of income and was not material. The final fair value of assets acquired, including goodwill and intangibles, and liabilities assumed as of the acquisition date were as follows (in thousands): Amount Cash and cash equivalents $ 224 Other assets acquired 83 Tangible assets acquired 307 Other liabilities assumed (652) Deferred tax liability - non-current (1,131) Total net tangible assets acquired and liabilities assumed (1,476) Intangible assets 5,640 Goodwill 4,511 Net assets acquired $ 8,675 The intangible assets as of the acquisition date included (in thousands): Amount Weighted Average Useful Life (in years) Developed technology $ 5,500 10 Customer relationships 140 3 $ 5,640 The fair value of the intangible assets acquired in connection with the acquisition was determined using either the income or replacement cost methodologies. The developed technology and customer relationships will be amortized over ten years and three years, respectively. Identifiable Intangible Assets Developed technology acquired primarily consists of existing technology related to developing reagents for precise monitoring of antigen-specific T-cells in research and development, enabling the Company to strengthen its efforts in immunology. The Company valued the developed technology using the multi-period excess earnings method under the income approach. Using this approach, the final fair values were calculated using expected future cash flows discounted to their net present values at an appropriate risk-adjusted rate of return. Goodwill The excess of purchase price over the fair value assigned to the assets acquired and liabilities assumed represents the amount of goodwill resulting from the acquisition. We do not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to the acquisition was recorded as a noncurrent asset and is not amortized but is subject to an annual review for impairment. 2020 Acquisitions ReadCoor Acquisition On October 13, 2020, the Company purchased all of the outstanding shares of ReadCoor Inc. (“ReadCoor”), a privately held company based in Cambridge, MA, for $407.4 million, inclusive of $1.6 million of transaction costs and net of cash acquired of $9.2 million. The total purchase consideration comprised of $101.4 million in cash and $306.0 million in shares of the Company's common stock. The purchase agreement provided for the Company to issue 1,901,382 shares of the Company’s class A common stock which was based on a contractual value of $250.0 million divided by the ten-day weighted average price of the Company's common stock shortly prior to the acquisition. In determining the total purchase consideration paid for ReadCoor, these shares were valued at $306.0 million based on the fair value of the Company’s class A common stock on the acquisition date. ReadCoor is developing In Situ RNA analysis technology, consisting of a suite of proprietary reagents, which aims to enable researchers to visualize spatially resolved RNA expression profiles with sub-cellular resolution throughout fresh frozen or formalin-fixed, paraffin-embedded tissue sections. The transaction was accounted for as an asset acquisition. In connection with this acquisition, the Company acquired an in-process research and development intangible asset of $406.9 million which did not have alternative future use and therefore was recognized as an expense and included as a component of in-process research and development in the consolidated statements of operations and comprehensive loss. The Company also acquired an intangible asset of $0.9 million related to assembled workforce which is included in other noncurrent assets in the consolidated balance sheets. The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process research and development $ 406,911 Intangible asset 927 Other assets and liabilities, net (406) Total net assets acquired $ 407,432 CartaNA Acquisition On August 21, 2020, the Company purchased all of the outstanding shares of CartaNA AB (“CartaNA”), a privately held company based in Stockholm, Sweden, for $41.8 million, inclusive of $0.6 million of transaction costs and net of cash acquired of $1.5 million. CartaNA is developing In Situ RNA analysis technology, consisting of a suite of proprietary reagents, which aims to enable researchers to visualize spatially resolved RNA expression profiles with sub-cellular resolution throughout fresh frozen or formalin-fixed, paraffin-embedded tissue sections. The transaction was accounted for as an asset acquisition. In connection with this acquisition, the Company acquired an in-process research and development intangible asset of $40.6 million which did not have alternative future use and therefore was recognized as an expense and included as a component of in-process research and development in the consolidated statements of operations and comprehensive loss. The Company also acquired $0.8 million in intangible assets related to customer relationships and assembled workforce which are included in other noncurrent assets in the consolidated balance sheets. The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process research and development $ 40,637 Intangible assets 801 Other assets and liabilities, net 348 Total net assets acquired $ 41,786

Other Financial Statement Infor

Other Financial Statement Information	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Inventory Inventory was comprised of the following (in thousands): Year Ended December 31, 2021 2020 Purchased materials $ 31,954 $ 9,930 Work in progress 14,052 9,312 Finished goods 13,960 10,717 Inventory $ 59,966 $ 29,959 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Year Ended December 31, 2021 2020 Land $ 36,099 $ — Laboratory equipment and machinery 44,189 30,010 Computer equipment 12,294 5,783 Furniture and fixtures 6,208 5,887 Leasehold improvements 67,532 42,068 Construction in progress 52,191 19,594 Total property and equipment 218,513 103,342 Less: accumulated depreciation and amortization (49,021) (30,502) Property and equipment, net $ 169,492 $ 72,840 Depreciation expense was $18.5 million, $12.3 million and $6.7 million for the years ended December 31, 2021, 2020, and 2019, respectively. Intangible Assets, Net Intangible assets, net, which are recorded within other noncurrent assets in the consolidated balance sheets, consisted of the following (dollars in thousands): December 31, 2021 December 31, 2020 Remaining Useful Life in Years Gross Accumulated Intangibles, Gross Accumulated Intangibles, Technology licenses 12.7 $ 22,504 $ (3,506) $ 18,998 $ 22,504 $ (1,973) $ 20,531 Developed technology 9.0 5,500 (550) 4,950 — — — Customer relationships 2.8 945 (337) 608 805 (111) 694 Trademarks — 204 (204) — 204 (142) 62 Assembled workforce 3.8 1,128 (287) 841 1,128 (61) 1,067 Intangible assets, net $ 30,281 $ (4,884) $ 25,397 $ 24,641 $ (2,287) $ 22,354 The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2022 $ 2,535 2023 2,506 2024 2,378 2025 2,214 2026 2,024 Thereafter 13,740 Total $ 25,397 Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures and asset impairments, among other factors. Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following (in thousands): Year Ended December 31, 2021 2020 Accrued payroll and related costs $ 3,978 $ 2,506 Employee stock purchase program liability 1,693 1,258 Accrued bonus 16,558 5,058 Accrued commissions 3,417 3,038 Accrued acquisition-related compensation 4,430 2,213 Accrued vacation 1,172 1,035 Other 378 275 Accrued compensation and related benefits $ 31,626 $ 15,383 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): Year Ended December 31, 2021 2020 Accrued legal and related costs $ 2,425 $ 5,704 Accrued license fee 6,214 6,198 Accrued purchase consideration — 4,146 Accrued royalties for licensed technologies 4,415 3,160 Accrued property and equipment 15,361 2,983 Accrued professional services 8,593 3,137 Product warranties 994 399 Customer deposits 954 1,727 Taxes payable 4,622 8,649 Accrued lab supplies 2,056 1,506 Other 5,275 5,844 Accrued expenses and other current liabilities $ 50,909 $ 43,453 Product Warranties Changes in the reserve for product warranties were as follows (in thousands): Year Ended December 31, 2021 2020 Beginning of period $ 399 $ 467 Amounts charged to cost of revenue 2,934 796 Repairs and replacements (2,339) (864) End of period $ 994 $ 399 Revenue and Deferred Revenue As of December 31, 2021, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $7.7 million, of which approximately $5.3 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $7.7 million and $6.2 million as of December 31, 2021 and December 31, 2020, respectively, consisted of deferred revenue related to extended warranty service agreements. A summary of the change in contract liabilities is as follows (in thousands): Year Ended December 31, 2021 2020 Beginning of period $ 6,154 $ 4,131 Revenue recognized that was included in the contract liability at the beginning of the year (4,101) (3,295) Revenue deferred excluding amounts recognized as revenue during the period 5,635 5,318 Balance as of December 31 $ 7,688 $ 6,154 The following table represents revenue by source for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 Instruments $ 64,474 $ 40,128 $ 34,945 Consumables 418,740 252,685 206,878 Services 7,276 6,032 4,070 Total revenue $ 490,490 $ 298,845 $ 245,893 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 United States $ 258,274 $ 154,768 $ 133,266 Europe, Middle East and Africa 108,491 73,265 58,004 China 74,924 41,741 29,920 Asia-Pacific (excluding China) 42,087 24,507 18,211 North America (excluding United States) 6,714 4,564 6,492 Total revenue $ 490,490 $ 298,845 $ 245,893

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	Debt In September 2016, the Company entered into a Second Amended and Restated Loan and Security Agreement with Silicon Valley Bank (as amended and restated in February 2018 and as further amended, restated or supplemented from time to time, the “Loan and Security Agreement”), which included a term loan and revolving line of credit. On February 20, 2020, the Company repaid the remaining balance of the term loan and all associated costs. The final payment of $30.5 million included $28.3 million for the outstanding principal balance of the term loan, $1.8 million for an end of term payment, $0.3 million for early termination fees and $0.1 million for interest. The prepayment resulted in a loss on extinguishment of debt of $1.5 million. The non-accreted portion of the end of term payment, unamortized discounts and early termination fees were included in the calculation of the loss on extinguishment of debt. The revolving line of credit and the Loan and Security Agreement was terminated at the election of the Company on June 18, 2020. Upon termination, the Company incurred termination fees of $0.3 million.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax	Income Tax Loss before provision for income taxes were as follows for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 United States $ (73,070) $ (376,835) $ (35,675) International 19,355 (157,641) 4,642 Total $ (53,715) $ (534,476) $ (31,033) The provision for income taxes consisted of the following (in thousands): Year Ended December 31, 2021 2020 2019 Current provision: Federal $ — $ — $ — State 50 — 98 Foreign 5,148 8,173 126 Total current provision for income taxes 5,198 8,173 224 Deferred provision: Federal — — — State — — — Foreign (690) 82 (6) Total deferred provision for income taxes (690) 82 (6) Provision for income taxes $ 4,508 $ 8,255 $ 218 The provision for income taxes was $4.5 million for the year ended December 31, 2021, which related to foreign and state income taxes. For the years ended December 31, 2020 and 2019, the provision for income taxes were $8.3 million and $0.2 million, respectively. A reconciliation of the federal statutory income tax provision to the effective income tax provision is as follows for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 Income tax provision at statutory rate $ (11,280) $ (112,240) $ (6,517) State taxes, net (20,136) (16,653) (2,958) Tax credits (11,836) (9,453) (2,684) Foreign taxes 142 41,253 101 Stock-based compensation (78,852) (52,070) 1,032 Change in valuation allowance 126,386 99,034 10,783 Acquisition related expenses (793) 93,407 116 Impact of change in tax status — (34,731) — Other 877 (292) 345 Total provision for income taxes $ 4,508 $ 8,255 $ 218 Deferred income taxes reflect the net tax effect of temporary differences between amounts recorded for financial reporting purposes and amounts used for tax purposes. The major components of deferred tax assets and liabilities are as follows as of the dates indicated (in thousands): Year Ended December 31, 2021 2020 Deferred tax assets Net operating loss carryforwards $ 195,953 $ 90,562 Research and development tax credits 54,117 31,908 Accruals and reserves 7,868 14,392 Lease liability 19,697 14,192 Intangibles 40,716 43,261 Stock-based compensation 12,261 6,601 Total deferred tax assets 330,612 200,916 Valuation allowance (313,194) (186,853) Net deferred tax assets $ 17,418 $ 14,063 Year Ended December 31, 2021 2020 Deferred tax liabilities Fixed assets $ (4,189) $ (3,750) Right-of-use assets (13,745) (10,388) Total deferred tax liabilities (17,934) (14,138) Net deferred tax liabilities $ (516) $ (75) As of December 31, 2021 and 2020, the Company maintained a full valuation allowance on its domestic net deferred tax assets. The domestic deferred tax assets predominantly relate to operating losses and tax credits. The domestic valuation allowance was estimated based on an assessment of both positive and negative evidence to determine whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses, required that a full valuation allowance be recorded against all domestic net deferred tax assets. The Company intends to maintain a full valuation allowance on domestic net deferred tax assets until sufficient positive evidence exists to support a reversal of the valuation allowance. The valuation allowance increased by $126.3 million and by $120.4 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company had federal net operating loss (NOL) carryforwards of $818.0 million and federal tax credit carryforwards of $45.8 million. The federal NOL carryforwards generated during and after fiscal 2018 totaling $703.1 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2021, the Company had state NOL carryforwards of $372.5 million, which begin to expire in 2033. In addition, the Company had state tax credit carryforwards of $35.3 million, which do not expire. The federal and state net operating losses and credit carryforwards are subject to change of ownership limitations provided by the Internal Revenue Code and similar state provisions. In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a 3-year period (a “Section 382 ownership change”), utilization of its pre-change NOL and credit carryforwards are subject to an annual limitation. The Company completed a study through October 31, 2021 and determined that a Section 382 ownership change occurred in 2013. As a result, the Company’s net operating losses generated through November 1, 2013 may be subject to limitation under Section 382 of the Code. The amount of pre-change loss carryforwards which may be subject to this limitation is $4.8 million. In addition certain attributes are subject to annual limitations as a result of the acquisition of ReadCoor, which constitutes a change in ownership as defined under Section 382. Such limitations may result in expiration of a portion of the carryforwards before utilization. The Company’s ability to use net operating loss carryforwards, research and development credit carryforwards and other tax attributes to reduce future taxable income and liabilities may be further limited as a result of future changes in stock ownership. As a result, if the Company earns net taxable income, its ability to use pre-change net operating loss carryforwards or other pre-change tax attributes to offset United States federal and state taxable income may still be subject to limitations, which could potentially result in increased future tax liability. The total balance of unrecognized gross tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed on the Company’s annual tax returns were as follows (in thousands): 2021 2020 Unrecognized tax benefits at beginning of year $ 14,657 $ 6,410 Reductions based on prior year tax provisions (252) (311) Additions based on current year tax provisions 9,354 8,558 Unrecognized tax benefits at end of year $ 23,759 $ 14,657 The total amount of unrecognized gross tax benefits was $23.8 million and $14.7 million as of December 31, 2021 and 2020, respectively, of which $1.5 million and $0.6 million, if recognized, would affect our effective tax rate, respectively. The Company is subject to the examination of its income tax returns by the U.S. Internal Revenue Service and other domestic and foreign tax authorities. The United States, California and Sweden are considered as major jurisdictions. The Company has not been audited in such jurisdictions. Tax examinations are expected to focus on research and development tax credits, intercompany transfer pricing practices and other matters. Due to NOLs and credit carryforwards, as of December 31, 2021, federal and California income tax returns for the years ended 2012 through the current period are open to examination. Significant foreign income tax returns for the years 2018 through the current period are open to examination. Due to the number of years remaining that are subject to examination, the Company is unable to estimate the full range of possible adjustments to the balance of gross unrecognized tax benefits. It is reasonably possible that the Company's unrecognized tax benefits will change significantly over the next 12 months, likely due to increases related to research and development tax credits. For U.S. uncertain tax positions, due to a full valuation allowance, such liabilities have been netted against deferred tax attribute carryovers. As a result, if recognized, the unrecognized tax benefits would not materially impact income tax expense. The Company includes interest and penalties related to income tax matters within the provision for income taxes. As of December 31, 2021, the total amount of gross interest and penalties accrued was $0.2 million. The Company recognized interest and penalty expenses of $0.2 million in 2021. The Company maintained undistributed earnings overseas as of December 31, 2021. As of December 31, 2021, the Company believed the funds held by all non-US subsidiaries will be permanently reinvested outside of the U.S. However, if these funds were repatriated to the U.S. or used for U.S. operations, the Company may be subject to withholding taxes in the foreign countries. As a result of tax reform, the Company’s unrepatriated earnings are no longer subject to federal income tax in the U.S. when distributed.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification From time to time, the Company has entered into indemnification provisions under certain agreements in the ordinary course of business, typically with business partners, customers and suppliers. Pursuant to these agreements, the Company may indemnify, hold harmless and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to the Company’s products. The Company maintains product liability insurance coverage that would generally enable it to recover a portion of the amounts paid. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding to which any of them are, or are threatened to be, made a party by reason of their service as a director or officer (see “—Litigation” below). The Company also may be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. Non-cancelable Purchase Commitments The Company’s contract manufacturer makes advance purchases of components based on the instrument unit forecasts and purchase orders placed by the Company. To the extent these components are purchased by the contract manufacturer on the Company’s behalf and cannot be used by their other customers, the Company is obligated to purchase these components. In addition, certain supplier agreements require that the Company to make minimum annual purchases under the agreements. As of December 31, 2021, the Company has commitments to make a total of $0.5 million in purchases over the next three years. To date, the Company has met the minimum purchase commitments. As of December 31, 2021, the Company has entered into non-cancelable arrangements for subscription software services and construction contracts associated with the development of buildings at our Springdale, Pleasanton site under which the Company has an obligation to make payments aggregating to $15.9 million and $16.3 million over the next five years. Intellectual Property Licensing In July 2021, the Company entered into a global settlement and patent cross license agreement with Bio-Rad laboratories, Inc. (see the 2021 Bio-Rad Settlement And Patent Cross License Agreement in this footnote for further details) pursuant to which both parties granted each other a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single cell analysis. Each company shall pay to the other royalties from licensed products and licensed services through 2030. In September 2020, the Company and the Board of Trustees of the Leland Stanford Junior University ("Stanford") entered into a license agreement pursuant to which the Company was granted a license to certain intellectual property from Stanford relating to single cell profiling and tissue clarification. As the Company receives revenue related to products covered by these licenses, it is required to pay Stanford a low single-digit royalty percentage based on the net revenue of certain products during the applicable term of the licensed patents. In October 2019, as part of the 2019 Becton Dickinson Settlement and Patent Cross License Agreement with Becton, Dickinson and Company and Cellular Research, Inc. (“BD Entities”), the Company was granted a worldwide royalty-free, nonexclusive license to certain intellectual property from the BD Entities. The Company recognized $22.1 million in technology licenses as an intangible asset with a weighted average amortization period of 15 years. This license is classified within other noncurrent assets on the Company’s consolidated balance sheet as of December 31, 2021. The minimum commitments related to the Company's license arrangements aggregate to $19.9 million as of December 31, 2021 to be paid over the next 17 years. Lease Agreements The Company leases office, laboratory, manufacturing, distribution and server space with lease terms up to 12 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. For the years ended December 31, 2021 and December 31, 2020, the Company incurred $10.5 million and $8.4 million, respectively, of operating lease costs and $0.6 million and $0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2021 and December 31, 2020 were $6.2 million and $7.1 million and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. The Company maintains letters of credit for the benefit of the landlord related to two of the Company’s non-cancelable operating leases, in the amount of $7.5 million in aggregate. The maturity of the Company’s operating lease liabilities as of December 31, 2021 is as follows (in thousands): Operating Leases 2022 $ 9,376 2023 12,237 2024 12,203 2025 11,225 2026 11,678 Thereafter 48,099 Total lease payments $ 104,818 Less: imputed interest (22,840) Present value of operating lease liabilities $ 81,978 Operating lease liabilities, current $ 5,131 Operating lease liabilities, noncurrent $ 76,847 The following table summarizes additional information related to operating leases as of December 31, 2021: December 31, 2021 December 31, 2020 Weighted-average remaining lease term: Operating leases 8.7 years 8.4 years Weighted-average discount rate: Operating leases 5.4 % 4.5 % On November 6, 2020, the Company entered into a Master Lease Agreement ("MLA") to lease additional office building space near the Company's Pleasanton, California headquarters. The Company intends to utilize the leased space of approximately 145,000 square feet to accommodate its future growth requirements. The MLA consists of various lease components, certain of which commenced during the year ended December 31, 2021. The remaining components are expected to commence on various dates within 2022 and 2023 and is expected to terminate on June 30, 2033 Total undiscounted payments for lease components commencing in fiscal years 2022 and 2023 will be $21.0 million and $14.0 million, respectively, with weighted-average expected lease terms of 12 years for 2022 and 11 years for 2023. On April 30, 2021, the Company entered into a lease agreement to lease office building space of approximately 22,000 square feet in Stockholm, Sweden to accommodate its future growth requirements. The Company expects the lease term to commence in January 2022 for a five-year term and expects total lease payments over the lease term to amount to approximately $5.6 million. The tables above do not include payments, lease term, or discount rates relating to any leases or lease components that have not yet commenced as of December 31, 2021. The Company will determine the classification for each lease component at the individual component's commencement date. All leases and lease components that have not yet commenced are expected to be classified as operating leases. Lease payments for leases not yet commenced as of December 31, 2021 is as follows (in thousands): Lease payments for leases not yet commenced 2022 $ 1,027 2023 2,827 2024 4,310 2025 4,154 2026 4,501 Thereafter 23,734 Total undiscounted lease payments $ 40,553 Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. The 2021 Bio-Rad Settlement And Patent Cross License Agreement Bio-Rad Laboratories, Inc. (“Bio-Rad”) and the Company were previously engaged in litigation and other proceedings relating to substantially all of the Company’s Chromium products, including the Company’s legacy GEM products and Next GEM products and multiple Bio-Rad products, around the world. On July 26, 2021, the Company entered into a Settlement and Patent Cross License Agreement (the “Bio-Rad Agreement”) with Bio-Rad resolving all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world and dismissing all infringement claims with prejudice. Pursuant to the terms of the Bio-Rad Agreement, Bio-Rad and the Company granted each other a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single cell analysis. The cross license excludes spatial and In Situ products. It also excludes digital PCR products in the case of 10x. The term of the Bio-Rad Agreement is for the life of the licensed patents. The Company and Bio-Rad have agreed not to sue each other on licensed products and licensed services on other patents owned or exclusively licensed by each company. The companies have agreed that each company’s patents are owned by each respective company. Each company shall pay to the other royalties from licensed products and licensed services through 2030. The Company previously accrued $44.8 million in royalties and interest between November 14, 2018 and March 31, 2021 related to sales of the Company’s GEM products as a result of the litigation with Bio-Rad. Pursuant to the Agreement, the Company paid Bio-Rad $29.4 million in royalties and interest related to the sales of such GEM products between November 14, 2018 and March 31, 2021. As a result, in connection with the Agreement the Company reversed $15.4 million in accrued royalties and interest as a reduction in cost of goods sold and operating expenses in the second quarter of 2021. The Nanostring Action On May 6, 2021, the Company filed suit against Nanostring Technologies, Inc. ("Nanostring") in the U.S. District Court for the District of Delaware alleging that Nanostring's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113, and 10,996,219. On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On July 1, 2021, Nanostring filed a motion to dismiss. On November 17, 2021, the Court held a hearing and dismissed without prejudice the Company's claims for pre-suit indirect infringement and willful infringement. Discovery is in progress. A Markman hearing is scheduled for October 2022 and trial is scheduled for June 2023. For further discussion of the risks relating to intellectual property and our pending litigation, see the section titled “ Risk Factors-Risks related to litigation and our intellectual property ” under Item 1A above.

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Capital Stock	Capital Stock The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 1,200,000,000 shares of capital stock consisting of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock, and 100,000,000 shares of preferred stock. Common Stock The Company has the following shares of common stock issued and outstanding: As of December 31, 2021 2020 Class A common stock 92,868,512 85,804,444 Class B common stock 19,646,465 22,681,465 Total common stock issued and outstanding 112,514,977 108,485,909 During the twelve months ended December 31, 2021 and December 31, 2020, 3,035,000 shares and 52,587,965 shares of Class B common stock, respectively, were converted to shares of Class A common stock upon the election of the holders of such shares. The Company’s Class A common stock and Class B common stock have a par value of $0.00001 per share. Each share of Class B common stock has the right to ten votes and each share of Class A common stock has the right to one vote per share. All other rights and privileges of Class A and Class B common stock are equivalent. Class B common shares are convertible to Class A common shares at any time upon written notification and all Class B common shares will convert upon the date specified by vote or written consent of the holders of a majority of the then outstanding Class B common stock, voting together as a single class. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends.

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans Amended and Restated 2012 Stock Plan Following the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the Amended and Restated 2012 Stock Plan continue to be governed by their existing terms but no further awards may be granted under the Amended and Restated 2012 Stock Plan. As of December 31, 2021, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan which includes shares issuable upon the exercise of outstanding awards was 6,010,212. 2019 Omnibus Incentive Plan The Omnibus Incentive Plan allows for the issuance of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”) or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of December 31, 2021, the number of shares of Class A common stock available for issuance under the 2019 Omnibus Incentive Plan was 3,500,786 shares issuable in connection with outstanding awards and 13,256,664 shares reserved for issuance in connection with grants of future awards. The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000. The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5% increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. Options under the Omnibus Incentive Plan have a contractual term of 10 years. The exercise price of an ISO and NSO shall not be less than 100% of the fair market value of the shares on the date of grant. A summary of the Company’s stock option activity under the Plans is as follows: Outstanding Options Weighted- Average Exercise Price Weighted- Aggregate Intrinsic Value Balance as of December 31, 2020 11,860,844 $ 18.86 7.6 $ 1,455,758,971 Granted 363,874 178.40 Exercised (3,584,934) 9.21 Cancelled (427,030) 35.54 Balance as of December 31, 2021 8,212,754 $ 29.28 6.8 $ 993,520,419 Vested and exercisable as of December 31, 2021 5,251,327 $ 17.14 6.3 $ 693,906,970 The weighted-average grant date fair value of options granted during the years ended December 31, 2021, 2020, and 2019 was $108.05, $45.02, and $13.20 per share, respectively. The total intrinsic value of stock options exercised was $572.2 million, $466.1 million and $30.5 million during the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, the total unrecognized stock-based compensation related to stock options was $86.5 million, which will be recognized over a weighted-average period of approximately two years. Stock Option Valuation Assumptions The fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following assumptions for the periods indicated: Year Ended December 31, 2021 2020 2019 Expected volatility 67% – 69% 60% – 71% 40% – 53% Risk-free interest rate 1.0% – 1.1% 0.3% – 1.7% 1.5% – 2.5% Expected term 6.0 – 6.1 years 5.3 – 6.9 years 5.0 – 6.9 years Expected dividend —% —% —% Restricted Stock Units The Company began granting restricted stock unit awards (“RSUs”) to employees and other service providers during 2020. RSU activity for the year ended December 31, 2021 is as follows: Restricted Stock Weighted-Average Balance as of December 31, 2020 823,947 $ 80.97 Granted 970,033 179.95 Vested (382,380) 114.11 Cancelled (113,356) 123.21 Outstanding as of December 31, 2021 1,298,244 $ 141.48 As of December 31, 2021, the total unrecognized stock-based compensation related to RSUs was $171.6 million, which will be recognized over a weighted-average period of approximately three years. 2019 Employee Stock Purchase Plan In July 2019, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders. The ESPP went into effect on September 11, 2019. Subject to any limitations contained therein, the ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their eligible compensation to purchase the Company’s Class A common stock at a discounted price per share. The ESPP generally provides for consecutive, overlapping 6-month offering periods. Unless otherwise determined by the administrator of the ESPP, a participant may not sell, transfer or otherwise dispose of any shares of the Company’s Class A common stock purchased under the ESPP for 12 months following the applicable exercise date. During the years ended December 31, 2021 and 2020, 61,764 and 163,727 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,084,859, which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1% described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2021, there were 2,857,556 shares available for issuance under the ESPP. For the years ended December 31, 2021 and 2020, the weighted average grant date fair values of the ESPP shares purchased, using the Black-Scholes option pricing model, were $43.39 and $16.61, respectively. The following assumptions were used in estimating the fair values of shares under the ESPP: Year Ended December 31, 2021 2020 2019 Expected volatility 47% – 69% 45% – 70% 52% Risk-free interest rate 0.04% – 0.06% 0.12% – 0.15% 1.85% Expected term (in years) 0.5 – 1.0 0.5 – 1.0 0.70 Expected dividend —% —% —% As of December 31, 2021, the total unrecognized stock-based compensation related to the ESPP was $0.9 million, which will be recognized over a weighted-average period of approximately 0.4 years. Stock-based Compensation The Company recorded stock-based compensation expense in the consolidated statement of operations for the periods presented as follows (in thousands): Year Ended December 31, 2021 2020 2019 Cost of revenue $ 3,231 $ 1,551 $ 325 Research and development 41,970 19,623 5,721 Selling, general and administrative 50,761 27,452 7,287 Total stock-based compensation expense $ 95,962 $ 48,626 $ 13,333

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit PlansThe Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company has not contributed to the plan.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Year Ended December 31, 2021 2020 2019 Stock options to purchase common stock 8,212,754 11,860,844 15,918,243 Shares subject to repurchase 18,750 68,750 138,250 Restricted stock units 1,298,244 823,947 — Contingent restricted shares — 236,484 — Shares committed under ESPP 13,368 10,939 56,159 Total 9,543,116 13,000,964 16,112,652

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, accounting for asset and business acquisitions and the valuation of stock-based compensation awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation may be affected. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Segment Information	Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.
Cash Equivalents and Restricted Cash	Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value. Short-term restricted cash of $1.0 million and long-term restricted cash of $7.6 million primarily represents cash on deposit with financial institutions as security for letters of credit outstanding for the benefit of the landlord related to the Company’s non-cancelable operating leases for its corporate headquarters (see “—Commitments and Contingencies” below).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)
Accounts Receivable, Net	Accounts Receivable, NetAccounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues.
Business Concentrations	Business Concentrations The Company’s instruments are mostly assembled and tested by a single contract manufacturer in Asia and the United States. The Company’s agreement with the contract manufacturers contains purchase commitments. In addition, the Company is reliant on several suppliers for key components for its reagent kits. A significant disruption in the operations of the contract manufacturers or suppliers may impact the production of the Company’s products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations, which may be partially mitigated by the contract manufacturer's ability to relocate operations from Asia location to United States.
Concentrations	Concentrations Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents held with large financial institutions in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of these financial institutions. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced material credit losses to date. For the years ended December 31, 2021, 2020, and 2019, no single customer represented more than 10% of revenue. As of December 31, 2021, one of the Company's distributors accounted for 11% of the Company’s outstanding accounts receivable. No other customer or distributor represented more than 10% of the Company’s outstanding accounts receivable as of December 31, 2021 and December 31, 2020. Substantially all the Company’s long-lived assets are located in the United States.
Inventory	Inventory Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s consolidated statements of operations.
Leases	Leases The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company gives consideration to its credit risk, term of the lease and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and costs of goods sold over the reasonably assured lease term. The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.
Internal-Use Software	Internal-Use Software The Company capitalizes costs incurred to develop internal-use software within fixed assets and commencing from 2020, began capitalizing costs to develop hosting arrangements within other noncurrent assets in the consolidated balance sheets. Costs incurred during the preliminary planning and evaluation and post implementation stages of the project are expensed as incurred. Costs incurred during the application development stage of the project are capitalized. These costs are amortized on a straight-line basis over the estimated useful life of the asset.
Property and Equipment, Net	Property and Equipment, NetProperty and equipment is stated at cost, net of accumulated depreciation.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or,
Product Warranties	Product Warranties The Company generally provides a one-year warranty on its instruments. The Company reviews its exposure to estimated warranty obligations associated with instrument sales and establishes an accrual based on historical product failure rates and actual warranty costs incurred. This expense is recorded as a component of cost of revenue in the consolidated statements of operations and comprehensive loss.
Deferred Revenue	Deferred Revenue Deferred revenue consists of payments received in advance of revenue recognition primarily related to instrument service agreements, also referred to as extended warranties. Revenue under these agreements is recognized over the related service period. Deferred revenue expected to be recognized during the 12 months following the balance sheet date is recorded as current portion of deferred revenue and the remaining portion is recorded as long-term.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.
Cost of Revenue	Cost of RevenueCost of revenue primarily consists of manufacturing costs incurred in the production process, including personnel and related costs, component materials, labor and overhead, packaging and delivery costs and allocated costs including facilities and information technology. In addition, cost of product revenue includes royalty costs for licensed technologies included in the Company’s products, warranty costs and provisions for slow-moving and obsolete inventory.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are included in the Company’s cost of revenue.
Research and Development	Research and Development Research and development costs are expensed in the period incurred. Research and development expense consists of personnel and related costs, independent contractor costs, laboratory supplies, equipment maintenance, prototype and materials expenses, amortization of developed technology and intangibles and allocated costs including facilities and information technology. See Note 3 for discussion of in-process research and development included on the consolidated statements of operations.
Advertising Costs	Advertising CostsAdvertising costs are expensed as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company’s stock-based compensation relates to stock options, restricted stock units (“RSUs”) and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). Stock-based compensation expense for its stock-based awards is based on their grant date fair value. The Company determines the fair value of RSUs based on the closing price of its stock, which is listed on Nasdaq, at the date of the grant. The Company estimates the fair value of stock option awards and stock purchase rights under an ESPP on the grant date using the Black-Scholes option-pricing model. The fair values of stock-based awards are recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company calculated the expected term using the simplified method, which is the mid-point between the vesting and contractual term. Due to the short trading period of the Company's stock, the Company has estimated volatility by reference to the historical volatilities of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award.
Foreign Currency	Foreign Currency For foreign subsidiaries where the functional currency is the local currency, assets and liabilities are translated to the U.S. dollar using month-end exchange rates, and revenue and expenses using average exchange rates. The adjustments resulting from these foreign currency translations are recorded in Accumulated other comprehensive gain (loss).
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply in the years in which those tax assets and liabilities are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. federal state and foreign tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. The Company’s participating securities included the Company’s convertible preferred stock, as the holders would have been entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend was paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.
Acquisitions	Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business in which case the transaction is accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date, and that the fair value of acquired intangibles be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the purchase price over the assigned fair values of the net assets acquired is recorded as goodwill. Goodwill is not amortized, rather assessed, at least annually, for impairment at a reporting unit level. During the goodwill impairment review, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting unit with the carrying value, including goodwill. If the carrying amounts of the reporting unit exceed the fair value, we record an impairment loss based on the difference. The Company accounts for an asset acquisition under ASC, Business Combinations Topic 805, Subtopic 50 , which requires the acquiring entity in an asset acquisition to recognize net assets based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition; any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on relative fair values. In-process research and development expense is expensed as incurred provided there is no alternative future use. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2021 2020 2019 Cash and cash equivalents $ 587,447 $ 663,603 $ 424,166 Restricted cash 8,626 25,041 52,327 Total cash, cash equivalents and restricted cash $ 596,073 $ 688,644 $ 476,493
Schedule of Property Plant and Equipment	Depreciation is computed using the straight-line method based on the estimated useful lives of the following assets: Useful Life (Years) Laboratory equipment and machinery 3 - 5 Computer equipment 2 - 3 Furniture and fixtures 3 Leasehold improvements 1 - 10 Property and equipment, net consisted of the following (in thousands): Year Ended December 31, 2021 2020 Land $ 36,099 $ — Laboratory equipment and machinery 44,189 30,010 Computer equipment 12,294 5,783 Furniture and fixtures 6,208 5,887 Leasehold improvements 67,532 42,068 Construction in progress 52,191 19,594 Total property and equipment 218,513 103,342 Less: accumulated depreciation and amortization (49,021) (30,502) Property and equipment, net $ 169,492 $ 72,840

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	The final fair value of assets acquired, including goodwill and intangibles, and liabilities assumed as of the acquisition date were as follows (in thousands): Amount Cash and cash equivalents $ 224 Other assets acquired 83 Tangible assets acquired 307 Other liabilities assumed (652) Deferred tax liability - non-current (1,131) Total net tangible assets acquired and liabilities assumed (1,476) Intangible assets 5,640 Goodwill 4,511 Net assets acquired $ 8,675 The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process research and development $ 406,911 Intangible asset 927 Other assets and liabilities, net (406) Total net assets acquired $ 407,432 The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process research and development $ 40,637 Intangible assets 801 Other assets and liabilities, net 348 Total net assets acquired $ 41,786
Schedule of Intangible Assets Acquired	The intangible assets as of the acquisition date included (in thousands): Amount Weighted Average Useful Life (in years) Developed technology $ 5,500 10 Customer relationships 140 3 $ 5,640

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory was comprised of the following (in thousands): Year Ended December 31, 2021 2020 Purchased materials $ 31,954 $ 9,930 Work in progress 14,052 9,312 Finished goods 13,960 10,717 Inventory $ 59,966 $ 29,959
Schedule of Property Plant and Equipment	Depreciation is computed using the straight-line method based on the estimated useful lives of the following assets: Useful Life (Years) Laboratory equipment and machinery 3 - 5 Computer equipment 2 - 3 Furniture and fixtures 3 Leasehold improvements 1 - 10 Property and equipment, net consisted of the following (in thousands): Year Ended December 31, 2021 2020 Land $ 36,099 $ — Laboratory equipment and machinery 44,189 30,010 Computer equipment 12,294 5,783 Furniture and fixtures 6,208 5,887 Leasehold improvements 67,532 42,068 Construction in progress 52,191 19,594 Total property and equipment 218,513 103,342 Less: accumulated depreciation and amortization (49,021) (30,502) Property and equipment, net $ 169,492 $ 72,840
Schedule of Intangible Assets Net	Intangible assets, net, which are recorded within other noncurrent assets in the consolidated balance sheets, consisted of the following (dollars in thousands): December 31, 2021 December 31, 2020 Remaining Useful Life in Years Gross Accumulated Intangibles, Gross Accumulated Intangibles, Technology licenses 12.7 $ 22,504 $ (3,506) $ 18,998 $ 22,504 $ (1,973) $ 20,531 Developed technology 9.0 5,500 (550) 4,950 — — — Customer relationships 2.8 945 (337) 608 805 (111) 694 Trademarks — 204 (204) — 204 (142) 62 Assembled workforce 3.8 1,128 (287) 841 1,128 (61) 1,067 Intangible assets, net $ 30,281 $ (4,884) $ 25,397 $ 24,641 $ (2,287) $ 22,354
Schedule of Annual Amortization of Intangible Assets	The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2022 $ 2,535 2023 2,506 2024 2,378 2025 2,214 2026 2,024 Thereafter 13,740 Total $ 25,397
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following (in thousands): Year Ended December 31, 2021 2020 Accrued payroll and related costs $ 3,978 $ 2,506 Employee stock purchase program liability 1,693 1,258 Accrued bonus 16,558 5,058 Accrued commissions 3,417 3,038 Accrued acquisition-related compensation 4,430 2,213 Accrued vacation 1,172 1,035 Other 378 275 Accrued compensation and related benefits $ 31,626 $ 15,383
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following (in thousands): Year Ended December 31, 2021 2020 Accrued legal and related costs $ 2,425 $ 5,704 Accrued license fee 6,214 6,198 Accrued purchase consideration — 4,146 Accrued royalties for licensed technologies 4,415 3,160 Accrued property and equipment 15,361 2,983 Accrued professional services 8,593 3,137 Product warranties 994 399 Customer deposits 954 1,727 Taxes payable 4,622 8,649 Accrued lab supplies 2,056 1,506 Other 5,275 5,844 Accrued expenses and other current liabilities $ 50,909 $ 43,453
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows (in thousands): Year Ended December 31, 2021 2020 Beginning of period $ 399 $ 467 Amounts charged to cost of revenue 2,934 796 Repairs and replacements (2,339) (864) End of period $ 994 $ 399
Change in Contract with Customer Asset and Liability Abstract	A summary of the change in contract liabilities is as follows (in thousands): Year Ended December 31, 2021 2020 Beginning of period $ 6,154 $ 4,131 Revenue recognized that was included in the contract liability at the beginning of the year (4,101) (3,295) Revenue deferred excluding amounts recognized as revenue during the period 5,635 5,318 Balance as of December 31 $ 7,688 $ 6,154
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 Instruments $ 64,474 $ 40,128 $ 34,945 Consumables 418,740 252,685 206,878 Services 7,276 6,032 4,070 Total revenue $ 490,490 $ 298,845 $ 245,893
Schedule of Revenue by Geography	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 United States $ 258,274 $ 154,768 $ 133,266 Europe, Middle East and Africa 108,491 73,265 58,004 China 74,924 41,741 29,920 Asia-Pacific (excluding China) 42,087 24,507 18,211 North America (excluding United States) 6,714 4,564 6,492 Total revenue $ 490,490 $ 298,845 $ 245,893

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Loss before provision for income taxes were as follows for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 United States $ (73,070) $ (376,835) $ (35,675) International 19,355 (157,641) 4,642 Total $ (53,715) $ (534,476) $ (31,033)
Schedule of Provision for Income Taxes	The provision for income taxes consisted of the following (in thousands): Year Ended December 31, 2021 2020 2019 Current provision: Federal $ — $ — $ — State 50 — 98 Foreign 5,148 8,173 126 Total current provision for income taxes 5,198 8,173 224 Deferred provision: Federal — — — State — — — Foreign (690) 82 (6) Total deferred provision for income taxes (690) 82 (6) Provision for income taxes $ 4,508 $ 8,255 $ 218
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the federal statutory income tax provision to the effective income tax provision is as follows for the periods indicated (in thousands): Year Ended December 31, 2021 2020 2019 Income tax provision at statutory rate $ (11,280) $ (112,240) $ (6,517) State taxes, net (20,136) (16,653) (2,958) Tax credits (11,836) (9,453) (2,684) Foreign taxes 142 41,253 101 Stock-based compensation (78,852) (52,070) 1,032 Change in valuation allowance 126,386 99,034 10,783 Acquisition related expenses (793) 93,407 116 Impact of change in tax status — (34,731) — Other 877 (292) 345 Total provision for income taxes $ 4,508 $ 8,255 $ 218
Schedule of Deferred Tax Assets and Liabilities	The major components of deferred tax assets and liabilities are as follows as of the dates indicated (in thousands): Year Ended December 31, 2021 2020 Deferred tax assets Net operating loss carryforwards $ 195,953 $ 90,562 Research and development tax credits 54,117 31,908 Accruals and reserves 7,868 14,392 Lease liability 19,697 14,192 Intangibles 40,716 43,261 Stock-based compensation 12,261 6,601 Total deferred tax assets 330,612 200,916 Valuation allowance (313,194) (186,853) Net deferred tax assets $ 17,418 $ 14,063 Year Ended December 31, 2021 2020 Deferred tax liabilities Fixed assets $ (4,189) $ (3,750) Right-of-use assets (13,745) (10,388) Total deferred tax liabilities (17,934) (14,138) Net deferred tax liabilities $ (516) $ (75)
Summary of Income Tax Contingencies	The total balance of unrecognized gross tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed on the Company’s annual tax returns were as follows (in thousands): 2021 2020 Unrecognized tax benefits at beginning of year $ 14,657 $ 6,410 Reductions based on prior year tax provisions (252) (311) Additions based on current year tax provisions 9,354 8,558 Unrecognized tax benefits at end of year $ 23,759 $ 14,657

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	The maturity of the Company’s operating lease liabilities as of December 31, 2021 is as follows (in thousands): Operating Leases 2022 $ 9,376 2023 12,237 2024 12,203 2025 11,225 2026 11,678 Thereafter 48,099 Total lease payments $ 104,818 Less: imputed interest (22,840) Present value of operating lease liabilities $ 81,978 Operating lease liabilities, current $ 5,131 Operating lease liabilities, noncurrent $ 76,847
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of December 31, 2021: December 31, 2021 December 31, 2020 Weighted-average remaining lease term: Operating leases 8.7 years 8.4 years Weighted-average discount rate: Operating leases 5.4 % 4.5 %
Schedule of Estimated Undiscounted Lease Payments for Operating Lease, Lease Not Yet Commenced	Lease payments for leases not yet commenced 2022 $ 1,027 2023 2,827 2024 4,310 2025 4,154 2026 4,501 Thereafter 23,734 Total undiscounted lease payments $ 40,553

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Common Stock Issued and Outstanding	The Company has the following shares of common stock issued and outstanding: As of December 31, 2021 2020 Class A common stock 92,868,512 85,804,444 Class B common stock 19,646,465 22,681,465 Total common stock issued and outstanding 112,514,977 108,485,909

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of the Company's stock option activity	A summary of the Company’s stock option activity under the Plans is as follows: Outstanding Options Weighted- Average Exercise Price Weighted- Aggregate Intrinsic Value Balance as of December 31, 2020 11,860,844 $ 18.86 7.6 $ 1,455,758,971 Granted 363,874 178.40 Exercised (3,584,934) 9.21 Cancelled (427,030) 35.54 Balance as of December 31, 2021 8,212,754 $ 29.28 6.8 $ 993,520,419 Vested and exercisable as of December 31, 2021 5,251,327 $ 17.14 6.3 $ 693,906,970
Stock Option Valuation Assumptions	The fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following assumptions for the periods indicated: Year Ended December 31, 2021 2020 2019 Expected volatility 67% – 69% 60% – 71% 40% – 53% Risk-free interest rate 1.0% – 1.1% 0.3% – 1.7% 1.5% – 2.5% Expected term 6.0 – 6.1 years 5.3 – 6.9 years 5.0 – 6.9 years Expected dividend —% —% —%
Summary of RSU activity	The Company began granting restricted stock unit awards (“RSUs”) to employees and other service providers during 2020. RSU activity for the year ended December 31, 2021 is as follows: Restricted Stock Weighted-Average Balance as of December 31, 2020 823,947 $ 80.97 Granted 970,033 179.95 Vested (382,380) 114.11 Cancelled (113,356) 123.21 Outstanding as of December 31, 2021 1,298,244 $ 141.48
Schedule of Fair value of the Employee Stock Purchase Plan	The following assumptions were used in estimating the fair values of shares under the ESPP: Year Ended December 31, 2021 2020 2019 Expected volatility 47% – 69% 45% – 70% 52% Risk-free interest rate 0.04% – 0.06% 0.12% – 0.15% 1.85% Expected term (in years) 0.5 – 1.0 0.5 – 1.0 0.70 Expected dividend —% —% —%
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the consolidated statement of operations for the periods presented as follows (in thousands): Year Ended December 31, 2021 2020 2019 Cost of revenue $ 3,231 $ 1,551 $ 325 Research and development 41,970 19,623 5,721 Selling, general and administrative 50,761 27,452 7,287 Total stock-based compensation expense $ 95,962 $ 48,626 $ 13,333

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Year Ended December 31, 2021 2020 2019 Stock options to purchase common stock 8,212,754 11,860,844 15,918,243 Shares subject to repurchase 18,750 68,750 138,250 Restricted stock units 1,298,244 823,947 — Contingent restricted shares — 236,484 — Shares committed under ESPP 13,368 10,939 56,159 Total 9,543,116 13,000,964 16,112,652

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Number of operating segment | segment	1
Restricted cash	$ 7,598,000	$ 8,474,000
Allowance for doubtful accounts	0	0
Impairment of long lived assets	0	0	$ 0
Advertising costs	4,700,000	1,900,000	1,500,000
Foreign currency transaction gains (losses)	(900,000)	1,300,000	$ 100,000
Restricted cash	$ 1,028,000	16,567,000
Accounts Receivable | Customer Concentration Risk | One Distributor
Concentration risk	11.00%
Restricted Cash For Letter Of Credit
Restricted cash	$ 7,600,000
Fair value, inputs, level 1 | Money Market Funds
Fair value of money market instruments	548,000,000	600,900,000
Unrealized gains (losses) on money market instruments	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 587,447	$ 663,603	$ 424,166
Restricted cash	8,626	25,041	52,327
Total cash, cash equivalents and restricted cash	$ 596,073	$ 688,644	$ 476,493	$ 70,088

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Company Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Laboratory equipment and machinery | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	3 years
Laboratory equipment and machinery | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	5 years
Computer equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	2 years
Computer equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	3 years
Leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	1 year
Leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	10 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 08, 2021	Oct. 13, 2020	Aug. 21, 2020
ReadCoor
Business Acquisition [Line Items]
Assets acquired and liabilities assumed		$ 407,432
Transaction costs		1,600
Cash acquired		9,200
Cash payments for asset acquisition		101,400
Purchase consideration, shares		$ 306,000
Shares issued for purchase agreement (in shares)		1,901,382
Common stock, contractual value		$ 250,000
Term for common stock, weighted average price		10 days
In-process research and development		$ 406,911
Intangible asset		$ 927
CartaNA
Business Acquisition [Line Items]
Assets acquired and liabilities assumed			$ 41,786
Transaction costs			600
Cash acquired			1,500
Cash payments for asset acquisition			41,800
In-process research and development			40,637
Intangible asset			$ 801
Tetramer Shop
Business Acquisition [Line Items]
Percentage of outstanding shares acquired	100.00%
Cash paid for acquisition	$ 8,500
Cash acquired	200
Estimated fair value of contingent consideration	$ 1,500
Payment term	2 years
Intangible asset	$ 5,640
Tetramer Shop | Developed technology
Business Acquisition [Line Items]
Weighted average amortization period of intangible asset	10 years
Intangible asset	$ 5,500
Tetramer Shop | Customer relationships
Business Acquisition [Line Items]
Weighted average amortization period of intangible asset	3 years
Intangible asset	$ 140

Acquisitions - Schedule of Asse

Acquisitions - Schedule of Assets Acquired and Liabilities Assumed, Including Goodwill and Intangibles (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 08, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 4,511		$ 0
Tetramer Shop
Business Acquisition [Line Items]
Cash and cash equivalents		$ 224
Other assets acquired		83
Tangible assets acquired		307
Other liabilities assumed		(652)
Deferred tax liability - non-current		(1,131)
Total net tangible assets acquired and liabilities assumed		(1,476)
Intangible assets		5,640
Goodwill		4,511
Net assets acquired		$ 8,675

Acquisitions - Intangible Asset

Acquisitions - Intangible Assets Acquired (Details) - Tetramer Shop $ in Thousands	Jan. 08, 2021USD ($)
Business Acquisition [Line Items]
Intangible asset	$ 5,640
Developed technology
Business Acquisition [Line Items]
Intangible asset	$ 5,500
Weighted average amortization period of intangible asset	10 years
Customer relationships
Business Acquisition [Line Items]
Intangible asset	$ 140
Weighted average amortization period of intangible asset	3 years

Acquisitions - Summary of Asset

Acquisitions - Summary of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Oct. 13, 2020	Aug. 21, 2020
ReadCoor
Business Acquisition [Line Items]
In-process research and development	$ 406,911
Intangible asset	927
Other assets and liabilities, net	(406)
Total net assets acquired	$ 407,432
CartaNA
Business Acquisition [Line Items]
In-process research and development		$ 40,637
Intangible asset		801
Other assets and liabilities, net		348
Total net assets acquired		$ 41,786

Other Financial Statement Inf_3

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 31,954	$ 9,930
Work in progress	14,052	9,312
Finished goods	13,960	10,717
Inventory	$ 59,966	$ 29,959

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 218,513	$ 103,342
Less: accumulated depreciation and amortization	(49,021)	(30,502)
Property and equipment, net	169,492	72,840
Land
Property, Plant and Equipment [Line Items]
Total property and equipment	36,099	0
Laboratory equipment and machinery
Property, Plant and Equipment [Line Items]
Total property and equipment	44,189	30,010
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	12,294	5,783
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	6,208	5,887
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	67,532	42,068
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 52,191	$ 19,594

Other Financial Statement Inf_5

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense	$ 18,500	$ 12,300	$ 6,700
Transaction price allocated to remaining performance obligations	7,700
Contract liability	7,688	6,154	$ 4,131
Contract with customer, liability, revenue recognized	$ 4,101	$ 3,295

Other Financial Statement Inf_6

Other Financial Statement Information - Intangible Assets, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 30,281	$ 24,641
Accumulated Amortization	(4,884)	(2,287)
Intangibles, Net	$ 25,397	22,354
Technology licenses
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	12 years 8 months 12 days
Gross Carrying Amount	$ 22,504	22,504
Accumulated Amortization	(3,506)	(1,973)
Intangibles, Net	$ 18,998	20,531
Developed technology
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	9 years
Gross Carrying Amount	$ 5,500	0
Accumulated Amortization	(550)	0
Intangibles, Net	$ 4,950	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	2 years 9 months 18 days
Gross Carrying Amount	$ 945	805
Accumulated Amortization	(337)	(111)
Intangibles, Net	608	694
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	204	204
Accumulated Amortization	(204)	(142)
Intangibles, Net	$ 0	62
Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	3 years 9 months 18 days
Gross Carrying Amount	$ 1,128	1,128
Accumulated Amortization	(287)	(61)
Intangibles, Net	$ 841	$ 1,067

Other Financial Statement Inf_7

Other Financial Statement Information - Annual Amortization Of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets Amortization [Abstract]
2022	$ 2,535
2023	2,506
2024	2,378
2025	2,214
2026	2,024
Thereafter	13,740
Intangibles, Net	$ 25,397	$ 22,354

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 3,978	$ 2,506
Employee stock purchase program liability	1,693	1,258
Accrued bonus	16,558	5,058
Accrued commissions	3,417	3,038
Accrued acquisition-related compensation	4,430	2,213
Accrued vacation	1,172	1,035
Other	378	275
Accrued compensation and related benefits	$ 31,626	$ 15,383

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal and related costs	$ 2,425	$ 5,704
Accrued license fee	6,214	6,198
Accrued purchase consideration	0	4,146
Accrued royalties for licensed technologies	4,415	3,160
Accrued property and equipment	15,361	2,983
Accrued professional services	8,593	3,137
Product warranties	994	399
Customer deposits	954	1,727
Taxes payable	4,622	8,649
Accrued lab supplies	2,056	1,506
Other	5,275	5,844
Accrued expenses and other current liabilities	$ 50,909	$ 43,453

Other Financial Statement In_10

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 399	$ 467
Amounts charged to cost of revenue	2,934	796
Repairs and replacements	(2,339)	(864)
End of period	$ 994	$ 399

Other Financial Statement In_11

Other Financial Statement Information - Revenue Recognition (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 5,340	$ 4,472
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 5,300
Expected period of revenue recognition	12 months

Other Financial Statement In_12

Other Financial Statement Information - Summary Of The Change In Contract Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Contract with Customer, Liability [Roll Forward]
Balance as of January 1	$ 6,154	$ 4,131
Revenue recognized that was included in the contract liability at the beginning of the year	(4,101)	(3,295)
Revenue deferred excluding amounts recognized as revenue during the period	5,635	5,318
Balance as of December 31	$ 7,688	$ 6,154

Other Financial Statement In_13

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Product Information [Line Items]
Revenue	$ 490,490	$ 298,845	$ 245,893
Instruments
Product Information [Line Items]
Revenue	64,474	40,128	34,945
Consumables
Product Information [Line Items]
Revenue	418,740	252,685	206,878
Services
Product Information [Line Items]
Revenue	$ 7,276	$ 6,032	$ 4,070

Other Financial Statement In_14

Other Financial Statement Information - Schedule of Revenue by geography (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 490,490	$ 298,845	$ 245,893
United States
Disaggregation of Revenue [Line Items]
Revenue	258,274	154,768	133,266
Europe, Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	108,491	73,265	58,004
China
Disaggregation of Revenue [Line Items]
Revenue	74,924	41,741	29,920
Asia-Pacific (excluding China)
Disaggregation of Revenue [Line Items]
Revenue	42,087	24,507	18,211
North America (excluding United States)
Disaggregation of Revenue [Line Items]
Revenue	$ 6,714	$ 4,564	$ 6,492

Debt - Additional information (

Debt - Additional information (Detail) - USD ($) $ in Thousands	Jun. 18, 2020	Feb. 20, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ (1,521)	$ 0
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, termination fee	$ 300
Tranche A | Term Loan
Debt Instrument [Line Items]
Early payment of debt		$ 30,500
Early payment of debt principal amount		28,300
Early payment, term payment		1,800
Early payment of debt termination fees		300
Early payment of debt interest amount		100
Loss on extinguishment of debt		$ 1,500

Income Tax - Summary Of Loss Be

Income Tax - Summary Of Loss Before Provision For Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Loss Before Provision For Income Taxes	$ (53,715)	$ (534,476)	$ (31,033)
United States
Income Tax Contingency [Line Items]
Loss Before Provision For Income Taxes	(73,070)	(376,835)	(35,675)
International
Income Tax Contingency [Line Items]
Loss Before Provision For Income Taxes	$ 19,355	$ (157,641)	$ 4,642

Income Tax - Provision for Inco

Income Tax - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current provision:
Federal	$ 0	$ 0	$ 0
State	50	0	98
Foreign	5,148	8,173	126
Total current provision for income taxes	5,198	8,173	224
Deferred provision:
Federal	0	0	0
State	0	0	0
Foreign	(690)	82	(6)
Total deferred provision for income taxes	(690)	82	(6)
Total provision for income taxes	$ 4,508	$ 8,255	$ 218

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 01, 2013
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 4,508	$ 8,255	$ 218
Change in valuation allowance	126,300	120,400
Operating loss carryforwards, limitation amount				$ 4,800
Unrecognized gross tax benefits	23,759	14,657	$ 6,410
Unrecognized gross tax benefit that would affect effective tax rate if recognized	1,500	600
Interest and penalties accrued	200
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	818,000	$ 703,100
Tax credit carryforward	45,800
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	372,500
Tax credit carryforward	$ 35,300

Income Tax - Summary Of Reconci

Income Tax - Summary Of Reconciliation Of The Federal Statutory Income Tax Provision (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax provision at statutory rate	$ (11,280)	$ (112,240)	$ (6,517)
State taxes, net	(20,136)	(16,653)	(2,958)
Tax credits	(11,836)	(9,453)	(2,684)
Foreign taxes	142	41,253	101
Stock-based compensation	(78,852)	(52,070)	1,032
Change in valuation allowance	126,386	99,034	10,783
Acquisition related expenses	(793)	93,407	116
Impact of change in tax status	0	(34,731)	0
Other	877	(292)	345
Total provision for income taxes	$ 4,508	$ 8,255	$ 218

Income Tax - Summary Of Major C

Income Tax - Summary Of Major Components Of Deferred Tax Assets And Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets
Net operating loss carryforwards	$ 195,953	$ 90,562
Research and development tax credits	54,117	31,908
Accruals and reserves	7,868	14,392
Lease liability	19,697	14,192
Intangibles	40,716	43,261
Stock-based compensation	12,261	6,601
Total deferred tax assets	330,612	200,916
Valuation allowance	(313,194)	(186,853)
Net deferred tax assets	17,418	14,063
Deferred tax liabilities
Fixed assets	(4,189)	(3,750)
Right-of-use assets	(13,745)	(10,388)
Total deferred tax liabilities	(17,934)	(14,138)
Net deferred tax liabilities	$ (516)	$ (75)

Income Tax - Summary Of Unrecog

Income Tax - Summary Of Unrecognized Gross Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits at beginning of year	$ 14,657	$ 6,410
Reductions based on prior year tax provisions	(252)	(311)
Additions based on current year tax provisions	9,354	8,558
Unrecognized tax benefits at end of year	$ 23,759	$ 14,657

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) ft² in Thousands, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended			117 Months Ended
	Oct. 31, 2019USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2030USD ($)	Apr. 30, 2021USD ($)ft²	Mar. 31, 2021USD ($)	Nov. 06, 2020ft²
Minimum purchase commitment			$ 500
Operating lease cost			10,500	$ 8,400
Variable lease cost			600	400
Operating lease payments			6,200	7,100
Accrual provision			(660)	$ 1,270	$ 1,502
Software Development
Contractual obligation			15,900
Construction
Contractual obligation			$ 16,300
Maximum
Operating lease term			12 years
Pleasanton, California
Lease payment commencing 2022			$ 21,000
Lease payment commencing 2023			$ 14,000
2022 | Pleasanton, California
Weighted-average expected lease terms			12 years
2023 | Pleasanton, California
Weighted-average expected lease terms			11 years
Office building near headquarters
Lease payment commencing 2022			$ 1,027
Lease payment commencing 2023			2,827
Operating lease not yet commenced			40,553
Office building near headquarters | Pleasanton, California
Real estate property, area | ft²									145
Office building near headquarters | Stockholm, Sweden
Real estate property, area | ft²							22
Weighted-average expected lease terms							5 years
Operating lease not yet commenced							$ 5,600
Bio-Rad
Loss contingency								$ 44,800
Accrual provision		$ 15,400
Bio-Rad | Forecast
Loss contingency payments						$ 29,400
Letter of Credit
Letter of credit maximum borrowing capacity			7,500
Intellectual Property
Minimum purchase commitment			$ 19,900
BD Entities
Weighted average amortization period of intangible asset	15 years
BD Entities | Intellectual Property
Fair value of asset acquired	$ 22,100

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 9,376
2023	12,237
2024	12,203
2025	11,225
2026	11,678
Thereafter	48,099
Total lease payments	104,818
Less: imputed interest	(22,840)
Present value of operating lease liabilities	81,978
Operating lease liabilities, current	5,131
Operating lease liabilities, noncurrent	$ 76,847

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Details)	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term, operating leases	8 years 8 months 12 days	8 years 4 months 24 days
Weighted-average discount rate, operating leases	5.40%	4.50%

Commitments and Contingencies_4

Commitments and Contingencies - Estimated Undiscounted Lease Payments (Details) - Office building near headquarters $ in Thousands	Dec. 31, 2021USD ($)
Lessee, Lease, Description [Line Items]
2022	$ 1,027
2023	2,827
2024	4,310
2025	4,154
2026	4,501
Thereafter	23,734
Total undiscounted lease payments	$ 40,553

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021vote$ / sharesshares	Dec. 31, 2020$ / sharesshares
Class of Stock [Line Items]
Shares of capital stock authorized (in shares)	1,200,000,000
Common stock authorized (in shares)	1,100,000,000	1,100,000,000
Preferred stock authorized (in shares)	100,000,000	100,000,000
Common stock par value (in dollars per share) | $ / shares	$ 0.00001	$ 0.00001
Common Class A
Class of Stock [Line Items]
Common stock authorized (in shares)	1,000,000,000
Common stock par value (in dollars per share) | $ / shares	$ 0.00001
Number of votes per share | vote	1
Common Class B
Class of Stock [Line Items]
Common stock authorized (in shares)	100,000,000
Common stock shares converted (in shares)	3,035,000	52,587,965
Common stock par value (in dollars per share) | $ / shares	$ 0.00001
Number of votes per share | vote	10
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock authorized (in shares)	100,000,000

Capital Stock - Schedule of Com

Capital Stock - Schedule of Common Stock Issued and Outstanding (Details) - shares	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock issued (in shares)	112,514,977	108,485,909
Common stock outstanding (in shares)	112,514,977	108,485,909
Common Class A
Class of Stock [Line Items]
Common stock issued (in shares)	92,868,512	85,804,444
Common stock outstanding (in shares)	92,868,512	85,804,444
Common class B
Class of Stock [Line Items]
Common stock issued (in shares)	19,646,465	22,681,465
Common stock outstanding (in shares)	19,646,465	22,681,465

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted stock units
Unrecognized stock-based compensation	$ 171.6
Weighted-average period of recognition for stock options	3 years
2019 Omnibus Incentive Plan
Percentage increase in shares on stock outstanding	5.00%
Contractual term	10 years
Stock options grant date fair value (in dollars per share)	$ 108.05	$ 45.02	$ 13.20
Intrinsic value of stock options exercised	$ 572.2	$ 466.1	$ 30.5
Unrecognized stock-based compensation	$ 86.5
Weighted-average period of recognition for stock options	2 years
2019 Omnibus Incentive Plan | Minimum
Exercise price percentage on fair market value	100.00%
2019 Employee Stock Purchase Plan
Percentage increase in shares on stock outstanding	1.00%
Stock options grant date fair value (in dollars per share)	$ 43.39	$ 16.61
Unrecognized stock-based compensation	$ 0.9
Weighted-average period of recognition for stock options	4 months 24 days
Employee contribution percentage	15.00%
Offering period	6 months
2019 Employee Stock Purchase Plan | Employee Stock
Common stock reserved for issuance (in shares)	2,857,556
Common Class A | 10x Genomics, Inc. 2012 Stock Plan
Common stock issuable upon the exercise of stock options (in shares)	6,010,212
Common Class A | 2019 Omnibus Incentive Plan
Common stock issuable upon the exercise of stock options (in shares)	13,256,664
Shares issuable in connection with outstanding awards (in shares)	3,500,786
Common stock reserved for issuance (in shares)	11,000,000
Share-based payment award, number of shares authorized (in shares)	11,000,000
Common Class A | 2019 Employee Stock Purchase Plan
Common stock reserved for issuance (in shares)	3,084,859
Common Class A | 2019 Employee Stock Purchase Plan | Employee Stock
Shares issued in period for previously outstanding awards (in shares)	61,764	163,727

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary Of Company's Stock Option Activity (Detail) - 2019 Omnibus Incentive Plan - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding Options
Outstanding options, Beginning balance (in shares)	11,860,844
Outstanding options, Granted (in shares)	363,874
Exercised (in shares)	(3,584,934)
Outstanding Options, Cancelled (in shares)	(427,030)
Outstanding options, Ending balance (in shares)	8,212,754	11,860,844
Weighted- Average Exercise Price
Weighted-Average Exercise Price, Beginning balance (in dollars per share)	$ 18.86
Weighted-Average Exercise Price, Granted (in dollars per share)	178.40
Weighted-Average Exercise Price, Exercised (in dollars per share)	9.21
Weighted-Average Exercise Price, Cancelled (in dollars per share)	35.54
Weighted-Average Exercise Price, Ending balance (in dollars per share)	$ 29.28	$ 18.86
Options Outstanding, Weighted-Average Remaining Terms (Years)	6 years 9 months 18 days	7 years 7 months 6 days
Options Outstanding, Aggregate Intrinsic Value	$ 993,520,419	$ 1,455,758,971
Weighted-Average Remaining Terms and Aggregate Intrinsic Value
Outstanding Options, Vested and exercisable (in shares)	5,251,327
Weighted-Average Exercise Price, Vested exercisable (in dollars per share)	$ 17.14
Options Outstanding, Weighted-Average Remaining Terms, Vested and exercisable	6 years 3 months 18 days
Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable	$ 693,906,970

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary Of Stock Option Valuation Assumptions (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	67.00%	60.00%	40.00%
Risk-free interest rate	1.00%	0.30%	1.50%
Expected term (in years)	6 years	5 years 3 months 18 days	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	69.00%	71.00%	53.00%
Risk-free interest rate	1.10%	1.70%	2.50%
Expected term (in years)	6 years 1 month 6 days	6 years 10 months 24 days	6 years 10 months 24 days

Equity Incentive Plans - Summ_3

Equity Incentive Plans - Summary of RSU Activity (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Restricted Stock Units
Restricted Stock Units, Beginning balance (in shares) | shares	823,947
Restricted Stock Units, Granted (in shares) | shares	970,033
Restricted Stock Units, Vested (in shares) | shares	(382,380)
Restricted Stock Units, Cancelled (in shares) | shares	(113,356)
Restricted Stock Units, Ending balance (in shares) | shares	1,298,244
Weighted-Average Grant Date Fair Value (per share)
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares	$ 80.97
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	179.95
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	114.11
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	123.21
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares	$ 141.48

Equity Incentive Plans - Summ_4

Equity Incentive Plans - Summary Of Fair Value Of The ESPP (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	67.00%	60.00%	40.00%
Risk-free interest rate	1.00%	0.30%	1.50%
Expected term (in years)	6 years	5 years 3 months 18 days	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	69.00%	71.00%	53.00%
Risk-free interest rate	1.10%	1.70%	2.50%
Expected term (in years)	6 years 1 month 6 days	6 years 10 months 24 days	6 years 10 months 24 days
2019 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			52.00%
Risk-free interest rate			1.85%
Expected term (in years)			8 months 12 days
Expected dividend	0.00%	0.00%	0.00%
2019 Employee Stock Purchase Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	47.00%	45.00%
Risk-free interest rate	0.04%	0.12%
Expected term (in years)	6 months	6 months
2019 Employee Stock Purchase Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	69.00%	70.00%
Risk-free interest rate	0.06%	0.15%
Expected term (in years)	1 year	1 year

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 95,962	$ 48,626	$ 13,333
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	3,231	1,551	325
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	41,970	19,623	5,721
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 50,761	$ 27,452	$ 7,287

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	9,543,116	13,000,964	16,112,652
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	8,212,754	11,860,844	15,918,243
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	18,750	68,750	138,250
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,298,244	823,947	0
Contingent restricted shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	236,484	0
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	13,368	10,939	56,159